BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-1177. [PMID: 11955534 DOI: 10.1016/s0140-6736(02)08213-2] [Cited by in Crossref: 697] [Cited by in F6Publishing: 237] [Article Influence: 36.7] [Reference Citation Analysis]
Number Citing Articles
1 Reiss AB, Cronstein BN. Regulation of foam cells by adenosine. Arterioscler Thromb Vasc Biol 2012;32:879-86. [PMID: 22423040 DOI: 10.1161/ATVBAHA.111.226878] [Cited by in Crossref: 46] [Cited by in F6Publishing: 16] [Article Influence: 5.1] [Reference Citation Analysis]
2 Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009;60:2870-9. [PMID: 19790070 DOI: 10.1002/art.24802] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 7.2] [Reference Citation Analysis]
3 Romão VC, Lima A, Bernardes M, Canhão H, Fonseca JE. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol Res 2014;60:289-310. [PMID: 25391609 DOI: 10.1007/s12026-014-8564-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
4 Lorenzatti A, Servato ML. Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Eur Cardiol 2018;13:38-41. [PMID: 30310469 DOI: 10.15420/ecr.2018.11.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013;13:80. [PMID: 23841877 DOI: 10.1186/1471-2377-13-80] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
6 Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther 2005;7:195-207. [PMID: 16207349 DOI: 10.1186/ar1814] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
7 De Vecchis R, Baldi C, Palmisani L. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatol J Cardiol 2016;16:2-9. [PMID: 26467356 DOI: 10.5152/akd.2015.6136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zimmerman MC, Clemens DL, Duryee MJ, Sarmiento C, Chiou A, Hunter CD, Tian J, Klassen LW, O'Dell JR, Thiele GM, Mikuls TR, Anderson DR. Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging. Redox Biol 2017;13:588-93. [PMID: 28803127 DOI: 10.1016/j.redox.2017.07.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
9 Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4. [PMID: 19208608 DOI: 10.3899/jrheum.080828] [Cited by in Crossref: 131] [Cited by in F6Publishing: 102] [Article Influence: 10.9] [Reference Citation Analysis]
10 Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467-1472. [PMID: 20159825 DOI: 10.1200/jco.2009.22.7918] [Cited by in Crossref: 255] [Cited by in F6Publishing: 150] [Article Influence: 23.2] [Reference Citation Analysis]
11 Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2015;74:415-21. [PMID: 24291654 DOI: 10.1136/annrheumdis-2013-204021] [Cited by in Crossref: 137] [Cited by in F6Publishing: 107] [Article Influence: 17.1] [Reference Citation Analysis]
12 Summers CM, Hammons AL, Arora J, Zhang S, Jochems J, Blair IA, Whitehead AS. Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol 2014;732:60-7. [PMID: 24657277 DOI: 10.1016/j.ejphar.2014.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2011;8:13-21. [PMID: 22083220 DOI: 10.1038/nrrheum.2011.168] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
14 Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB. How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. J Clin Med 2019;8:E515. [PMID: 30991730 DOI: 10.3390/jcm8040515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 12.5] [Reference Citation Analysis]
15 Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5. [PMID: 17158824 DOI: 10.1136/ard.2006.062497] [Cited by in Crossref: 150] [Cited by in F6Publishing: 112] [Article Influence: 10.0] [Reference Citation Analysis]
16 Choi IA, Lee JS, Song YW, Lee EY. Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide population-based study. PLoS One 2019;14:e0210471. [PMID: 30620765 DOI: 10.1371/journal.pone.0210471] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
17 Hoppe B, Dörner T. Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. Nat Rev Rheumatol 2012;8:738-46. [PMID: 23147903 DOI: 10.1038/nrrheum.2012.184] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
18 Stürmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. Rheumatology (Oxford) 2020;59:14-25. [PMID: 31834408 DOI: 10.1093/rheumatology/kez320] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
19 Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest 2017;127:83-93. [PMID: 28045401 DOI: 10.1172/JCI88884] [Cited by in Crossref: 65] [Cited by in F6Publishing: 27] [Article Influence: 16.3] [Reference Citation Analysis]
20 Whelan P. [Link between rheumatoid arthritis and cancer]. Z Rheumatol 2006;65:497-8, 500-2, 504. [PMID: 17004050 DOI: 10.1007/s00393-006-0105-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
21 Wang X, Yan X, Wang F, Ge F, Li Z. Role of methotrexate chronotherapy in collagen-induced rheumatoid arthritis in rats. Z Rheumatol 2018;77:249-55. [PMID: 27900440 DOI: 10.1007/s00393-016-0236-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Rodriguez-Rodriguez L, Ivorra-Cortes J, Carmona FD, Martín J, Balsa A, van Steenbergen HW, van der Helm-van Mil AH, González-Álvaro I, Fernandez-Gutiérrez B. PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts. Arthritis Res Ther 2015;17:306. [PMID: 26538147 DOI: 10.1186/s13075-015-0830-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
23 Beane OS, Darling LE, Fonseca VC, Darling EM. Disparate Response to Methotrexate in Stem Versus Non-Stem Cells. Stem Cell Rev Rep 2016;12:340-51. [PMID: 26815725 DOI: 10.1007/s12015-016-9645-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
24 Yki-Järvinen H, Bergholm R, Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003;62:630-4. [PMID: 12810424 DOI: 10.1136/ard.62.7.630] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
25 Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, Johnson D, Richards JS, Kerr GS, Cannon GW, Reimold A. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011;50:101-9. [PMID: 20659916 DOI: 10.1093/rheumatology/keq232] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
26 Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15. [PMID: 25969430 DOI: 10.1136/annrheumdis-2015-207524] [Cited by in Crossref: 713] [Cited by in F6Publishing: 506] [Article Influence: 118.8] [Reference Citation Analysis]
27 Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 2019;380:752-62. [PMID: 30415610 DOI: 10.1056/NEJMoa1809798] [Cited by in Crossref: 445] [Cited by in F6Publishing: 176] [Article Influence: 148.3] [Reference Citation Analysis]
28 Dourado E, Ferro M, Sousa Guerreiro C, Fonseca JE. Diet as a Modulator of Intestinal Microbiota in Rheumatoid Arthritis. Nutrients 2020;12:E3504. [PMID: 33202579 DOI: 10.3390/nu12113504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
29 Zha AM, Di Napoli M, Behrouz R. Prevention of Stroke in Rheumatoid Arthritis. Curr Neurol Neurosci Rep 2015;15:77. [PMID: 26486791 DOI: 10.1007/s11910-015-0600-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010;8:331-4. [PMID: 20367239 DOI: 10.1089/met.2009.0124] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
31 Romão VC, Canhão H, Fonseca JE. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med 2013;11:17. [PMID: 23343013 DOI: 10.1186/1741-7015-11-17] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
32 Shah PK, Lecis D. Inflammation in atherosclerotic cardiovascular disease. F1000Res 2019;8:F1000 Faculty Rev-1402. [PMID: 31448091 DOI: 10.12688/f1000research.18901.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
33 Goodson N, Symmons D. Rheumatoid arthritis in women: still associated with an increased mortality. Ann Rheum Dis 2002;61:955-6. [PMID: 12379514 DOI: 10.1136/ard.61.11.955] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
34 Mahyoodeen NG, Crowther NJ, Tikly M. Double trouble: psoriasis and cardiometabolic disorders. Cardiovasc J Afr 2018;29:189-94. [PMID: 29293257 DOI: 10.5830/CVJA-2017-055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009;4:e6242. [PMID: 19606218 DOI: 10.1371/journal.pone.0006242] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
36 Samimi Z, Kardideh B, Zafari P, Bahrehmand F, Roghani SA, Taghadosi M. The impaired gene expression of adenosine monophosphate-activated kinase (AMPK), a key metabolic enzyme in leukocytes of newly diagnosed rheumatoid arthritis patients. Mol Biol Rep 2019;46:6353-60. [PMID: 31541390 DOI: 10.1007/s11033-019-05078-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Kerola AM, Rollefstad S, Semb AG. Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment. Eur Cardiol 2021;16:e18. [PMID: 34040652 DOI: 10.15420/ecr.2020.44] [Reference Citation Analysis]
38 Bisoendial RJ, Stroes ES, Kastelein JJ, Tak PP. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 2010;6:157-64. [PMID: 20142814 DOI: 10.1038/nrrheum.2009.277] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
39 Dhillon N, Liang K. Prevention of stroke in rheumatoid arthritis. Curr Treat Options Neurol 2015;17:356. [PMID: 25981388 DOI: 10.1007/s11940-015-0356-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
40 Finckh A, Choi HK, Wolfe F. Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006;65:1192-7. [PMID: 16540549 DOI: 10.1136/ard.2005.049338] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 5.2] [Reference Citation Analysis]
41 Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 2007;26:1228-33. [PMID: 17273810 DOI: 10.1007/s10067-007-0548-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
42 Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2018;2:10. [PMID: 30886961 DOI: 10.1186/s41927-018-0014-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 12.7] [Reference Citation Analysis]
43 Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, Lapadula G, Iannone F. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. Mediators Inflamm 2018;2018:2453265. [PMID: 30405318 DOI: 10.1155/2018/2453265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
44 Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther. 2016;18:282. [PMID: 27906042 DOI: 10.1186/s13075-016-1176-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
45 Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep. 2013;10:21-32. [PMID: 23225316 DOI: 10.1007/s11904-012-0147-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
46 Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70. [PMID: 21855836 DOI: 10.1016/j.amjcard.2011.06.054] [Cited by in Crossref: 315] [Cited by in F6Publishing: 249] [Article Influence: 31.5] [Reference Citation Analysis]
47 Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, Xu C, MacFadyen J, Barbhaiya M, Berliner N, Dellaripa PF, Everett BM, Pradhan AD, Hammond SP, Murray M, Rao DA, Ritter SY, Rutherford A, Sparks JA, Stratton J, Suh DH, Tedeschi SK, Vanni KMM, Paynter NP, Ridker PM. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med 2020;172:369-80. [PMID: 32066146 DOI: 10.7326/M19-3369] [Cited by in Crossref: 41] [Cited by in F6Publishing: 15] [Article Influence: 41.0] [Reference Citation Analysis]
48 Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis. PLoS One 2020;15:e0235637. [PMID: 32628710 DOI: 10.1371/journal.pone.0235637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
49 Gingrich D, Deitchman AN, Kantor A, Huang L, Stein JH, Currier JS, Hsue PY, Ribaudo HJ, Aweeka FT; ACTG 5314 Protocol Team. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV. J Acquir Immune Defic Syndr 2020;85:651-8. [PMID: 33177476 DOI: 10.1097/QAI.0000000000002502] [Reference Citation Analysis]
50 Guo D, Shi C, Wang L, Ji X, Zhang S, Luo J. A Rationally Designed Micellar Nanocarrier for the Delivery of Hydrophilic Methotrexate in Psoriasis Treatment. ACS Appl Bio Mater 2020;3:4832-46. [PMID: 34136761 DOI: 10.1021/acsabm.0c00342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121:S9-14. [PMID: 18926169 DOI: 10.1016/j.amjmed.2008.06.011] [Cited by in Crossref: 151] [Cited by in F6Publishing: 124] [Article Influence: 11.6] [Reference Citation Analysis]
52 Nguyen MT, Fernando S, Schwarz N, Tan JT, Bursill CA, Psaltis PJ. Inflammation as a Therapeutic Target in Atherosclerosis. J Clin Med. 2019;8. [PMID: 31357404 DOI: 10.3390/jcm8081109] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 28.0] [Reference Citation Analysis]
53 Weinblatt ME. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003;62 Suppl 2:ii94-6. [PMID: 14532160 DOI: 10.1136/ard.62.suppl_2.ii94] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis]
54 Marks JL, Edwards CJ. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012;4:149-57. [PMID: 22850632 DOI: 10.1177/1759720X11436239] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
55 Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008;18:228-39. [PMID: 18437286 DOI: 10.1007/s10165-008-0056-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
56 Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open 2015;1:e000080. [PMID: 26535138 DOI: 10.1136/rmdopen-2015-000080] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
57 Hernán MA. How to estimate the effect of treatment duration on survival outcomes using observational data. BMJ 2018;360:k182. [PMID: 29419381 DOI: 10.1136/bmj.k182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
58 Mangoni AA, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence. Mediators Inflamm 2017;2017:9632846. [PMID: 29430085 DOI: 10.1155/2017/9632846] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
59 Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF. Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet 2016;55:297-311. [PMID: 26293618 DOI: 10.1007/s40262-015-0319-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
60 Adlan AM, Paton JF, Lip GY, Kitas GD, Fisher JP. Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. J Physiol 2017;595:967-81. [PMID: 27561790 DOI: 10.1113/JP272944] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 7.4] [Reference Citation Analysis]
61 Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009;68:367-72. [PMID: 18408253 DOI: 10.1136/ard.2007.076760] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 4.7] [Reference Citation Analysis]
62 Baker JF, Sauer BC, Cannon GW, Teng CC, Michaud K, Ibrahim S, Jorgenson E, Davis L, Caplan L, Cannella A, Mikuls TR. Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. Arthritis Rheumatol 2016;68:1818-27. [PMID: 26882094 DOI: 10.1002/art.39647] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
63 Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 2021;3:e58-70. [PMID: 32904897 DOI: 10.1016/S2665-9913(20)30221-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 24.0] [Reference Citation Analysis]
64 Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc 2016;5:e002867. [PMID: 26727968 DOI: 10.1161/JAHA.115.002867] [Cited by in Crossref: 74] [Cited by in F6Publishing: 29] [Article Influence: 14.8] [Reference Citation Analysis]
65 Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol 2013;25:317-24. [PMID: 23466960 DOI: 10.1097/BOR.0b013e32835fd7f8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
66 Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, Hessian PA. Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther 2012;14:R138. [PMID: 22682496 DOI: 10.1186/ar3871] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
67 Sosin M, Handa S. Low dose methotrexate and bone marrow suppression. BMJ. 2003;326:266-267. [PMID: 12560282 DOI: 10.1136/bmj.326.7383.266] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
68 Sack GH Jr. Serum amyloid A - a review. Mol Med 2018;24:46. [PMID: 30165816 DOI: 10.1186/s10020-018-0047-0] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 40.3] [Reference Citation Analysis]
69 Kolfenbach JR, Deane KD, Derber LA, O'Donnell C, Weisman MH, Buckner JH, Gersuk VH, Wei S, Mikuls TR, O'Dell J, Gregersen PK, Keating RM, Norris JM, Holers VM. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum 2009;61:1735-42. [PMID: 19950324 DOI: 10.1002/art.24833] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 8.5] [Reference Citation Analysis]
70 Davis LA, Cannon GW, Pointer LF, Haverhals LM, Wolff RK, Mikuls TR, Reimold AM, Kerr GS, Richards JS, Johnson DS, Valuck R, Prochazka A, Caplan L. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis. J Rheumatol 2013;40:809-17. [PMID: 23547211 DOI: 10.3899/jrheum.121012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
71 Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, Fernandez P, Cronstein BN, Chan ES. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008;58:3675-83. [PMID: 19035488 DOI: 10.1002/art.24040] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 8.8] [Reference Citation Analysis]
72 Schneider M, Krüger K. Rheumatoid arthritis--early diagnosis and disease management. Dtsch Arztebl Int 2013;110:477-84. [PMID: 23964304 DOI: 10.3238/arztebl.2013.0477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
73 van Wonderen KE, van der Mark LB, Mohrs J, Geskus RB, van der Wal WM, van Aalderen WM, Bindels PJ, ter Riet G. Prediction and treatment of asthma in preschool children at risk: study design and baseline data of a prospective cohort study in general practice (ARCADE). BMC Pulm Med 2009;9:13. [PMID: 19368704 DOI: 10.1186/1471-2466-9-13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
74 Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011;31:153-64. [PMID: 20390282 DOI: 10.1007/s00296-010-1446-x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 8.7] [Reference Citation Analysis]
75 Warrington KJ, Kent PD, Frye RL, Lymp JF, Kopecky SL, Goronzy JJ, Weyand CM. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther. 2005;7:R984-R991. [PMID: 16207339 DOI: 10.1186/ar1775] [Cited by in Crossref: 103] [Cited by in F6Publishing: 77] [Article Influence: 6.4] [Reference Citation Analysis]
76 Saraux A, Hudry C, Zinovieva E, Herman-Demars H; Self-I Investigators group. Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study. Rheumatol Ther 2019;6:47-60. [PMID: 30547379 DOI: 10.1007/s40744-018-0134-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
77 Scirè CA, Lunt M, Marshall T, Symmons DP, Verstappen SM. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2014;73:1677-82. [PMID: 23749581 DOI: 10.1136/annrheumdis-2013-203339] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
78 Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Hanly JG, Petri M, Steinsson K, Dooley MA, Manzi S, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Bruce IN. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013;72:1308-14. [PMID: 22945501 DOI: 10.1136/annrheumdis-2012-202106] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
79 Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006;65:1608-1612. [PMID: 16793844 DOI: 10.1136/ard.2005.050377] [Cited by in Crossref: 249] [Cited by in F6Publishing: 217] [Article Influence: 16.6] [Reference Citation Analysis]
80 Betancourt BY, Biehl A, Katz JD, Subedi A. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors. Rheum Dis Clin North Am 2018;44:371-91. [PMID: 30001781 DOI: 10.1016/j.rdc.2018.03.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
81 Neva MH, Häkkinen A, Mäkinen H, Hannonen P, Kauppi M, Sokka T. High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis. 2006;65:884-888. [PMID: 16269427 DOI: 10.1136/ard.2005.042135] [Cited by in Crossref: 88] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
82 Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008;59:1090-6. [PMID: 18668583 DOI: 10.1002/art.23935] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 6.1] [Reference Citation Analysis]
83 Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2008;10:213. [PMID: 18828865 DOI: 10.1186/ar2471] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
84 McInnes IB, McCarey DW, Sattar N. Do statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis 2004;63:1535-7. [PMID: 15547075 DOI: 10.1136/ard.2004.022061] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
85 Lunt M, Watson KD, Dixon WG, Symmons DP, Hyrich KL. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62:3145-3153. [PMID: 20662063 DOI: 10.1002/art.27660] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
86 Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006;60:578-86. [PMID: 16790829 DOI: 10.1136/jech.2004.029496] [Cited by in Crossref: 497] [Cited by in F6Publishing: 355] [Article Influence: 35.5] [Reference Citation Analysis]
87 Westreich D, Cole SR, Tien PC, Chmiel JS, Kingsley L, Funk MJ, Anastos K, Jacobson LP. Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol 2010;171:691-700. [PMID: 20139124 DOI: 10.1093/aje/kwp418] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
88 Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP. Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann Rheum Dis 2010;69:689-95. [PMID: 19858538 DOI: 10.1136/ard.2009.108639] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
89 Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S Jr, Reddy ST. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis Rheumatol 2017;69:46-57. [PMID: 27483410 DOI: 10.1002/art.39833] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
90 Fan JM, Solomon DA, López GY, Hofmann JW, Colorado RA, Kim AS, Meisel K, Halabi C. Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. BMC Neurol 2020;20:106. [PMID: 32199449 DOI: 10.1186/s12883-020-01681-9] [Reference Citation Analysis]
91 Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, Anis AH, Marra CA. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96. [PMID: 15733011 DOI: 10.2165/00003495-200565040-00004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
92 Liu D, Lv H, Liu Q, Sun Y, Hou S, Zhang L, Yang M, Han B, Wang G, Wang X, Du W, Nie H, Zhang R, Huang X, Hou J, Yu B. Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow. J Transl Med 2019;17:378. [PMID: 31730006 DOI: 10.1186/s12967-019-02135-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
93 Thornton CC, Al-Rashed F, Calay D, Birdsey GM, Bauer A, Mylroie H, Morley BJ, Randi AM, Haskard DO, Boyle JJ. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2015;Epub ahead of print. [PMID: 25575725 DOI: 10.1136/annrheumdis-2014-206305] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
94 Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:R30. [PMID: 18325087 DOI: 10.1186/ar2383] [Cited by in Crossref: 294] [Cited by in F6Publishing: 228] [Article Influence: 22.6] [Reference Citation Analysis]
95 Myasoedova E, Gabriel SE, Matteson EL, Davis JM 3rd, Therneau TM, Crowson CS. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? J Rheumatol 2017;44:732-9. [PMID: 28365576 DOI: 10.3899/jrheum.161154] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 10.5] [Reference Citation Analysis]
96 Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ; BIOBADASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5. [PMID: 17324968 DOI: 10.1136/ard.2006.067660] [Cited by in Crossref: 162] [Cited by in F6Publishing: 121] [Article Influence: 11.6] [Reference Citation Analysis]
97 Kuller LH, Mackey RH, Walitt BT, Deane KD, Holers VM, Robinson WH, Sokolove J, Chang Y, Liu S, Parks CG, Wright NC, Moreland LW. Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis. Arthritis Rheumatol 2014;66:497-507. [PMID: 24574208 DOI: 10.1002/art.38268] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
98 Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334-342. [PMID: 23044791 DOI: 10.1002/art.37723] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
99 Howe CJ, Cole SR, Mehta SH, Kirk GD. Estimating the effects of multiple time-varying exposures using joint marginal structural models: alcohol consumption, injection drug use, and HIV acquisition. Epidemiology 2012;23:574-82. [PMID: 22495473 DOI: 10.1097/EDE.0b013e31824d1ccb] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
100 Kolfenbach JR, Deane KD, Derber LA, O'Donnell CI, Gilliland WR, Edison JD, Rosen A, Darrah E, Norris JM, Holers VM. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum 2010;62:2633-9. [PMID: 20496417 DOI: 10.1002/art.27570] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 8.2] [Reference Citation Analysis]
101 Smolen JS, Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther 2009;11:204. [PMID: 19232060 DOI: 10.1186/ar2535] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
102 Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Säemann M, Schwarzinger I, Buranyi B, Steiner G, Smolen JS. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 2007;66:1284-8. [PMID: 17293363 DOI: 10.1136/ard.2006.066605] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
103 Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Setoguchi S, Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010;69:1920-5. [PMID: 20444756 DOI: 10.1136/ard.2009.122226] [Cited by in Crossref: 192] [Cited by in F6Publishing: 145] [Article Influence: 17.5] [Reference Citation Analysis]
104 Jednacz E, Rutkowska-Sak L. Atherosclerosis in juvenile idiopathic arthritis. Mediators Inflamm 2012;2012:714732. [PMID: 22933832 DOI: 10.1155/2012/714732] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
105 Rojas-Serrano J, Burgos-Vargas R, Pérez LL, García CG, Moctezuma F, Vázquez-Mellado J. Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Rheumatol 2009;28:1135-9. [PMID: 19504230 DOI: 10.1007/s10067-009-1206-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
106 Khan F, Galarraga B, Belch JJ. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol 2010;6:253-61. [PMID: 20351705 DOI: 10.1038/nrrheum.2010.44] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
107 Sun J, Dai S, Zhang L, Feng Y, Yu X, Zhang Z. Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China. Clin Rheumatol 2021;40:1789-98. [PMID: 33058034 DOI: 10.1007/s10067-020-05458-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Spinelli FR, Metere A, Barbati C, Pierdominici M, Iannuccelli C, Lucchino B, Ciciarello F, Agati L, Valesini G, Di Franco M. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators Inflamm 2013;2013:537539. [PMID: 24222719 DOI: 10.1155/2013/537539] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
109 van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151. [PMID: 16984661 DOI: 10.1186/ar2045] [Cited by in Crossref: 163] [Cited by in F6Publishing: 150] [Article Influence: 11.6] [Reference Citation Analysis]
110 Guan T, Qiu Z, Su M, Yang J, Tang Y, Jiang Y, Yao D, Lai Y, Li Y, Liu C. Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study. Front Oncol 2021;11:641955. [PMID: 34046345 DOI: 10.3389/fonc.2021.641955] [Reference Citation Analysis]
111 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482-9c. [PMID: 25433021 DOI: 10.1093/eurheartj/ehu403] [Cited by in Crossref: 190] [Cited by in F6Publishing: 131] [Article Influence: 27.1] [Reference Citation Analysis]
112 van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003;5:R347-51. [PMID: 14680509 DOI: 10.1186/ar1005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
113 Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report. Postepy Dermatol Alergol 2018;35:53-9. [PMID: 29599672 DOI: 10.5114/ada.2017.71358] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
114 Cavagna L, Boffini N, Cagnotto G, Inverardi F, Grosso V, Caporali R. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm 2012;2012:147354. [PMID: 23024462 DOI: 10.1155/2012/147354] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
115 Stamm TA, Reichardt B, Zwerina J, Ritschl V, Nell-Duxneuner V. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 : A retrospective analysis of 72% of the population. Wien Klin Wochenschr 2018;130:230-7. [PMID: 29445863 DOI: 10.1007/s00508-018-1321-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
116 Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141. [PMID: 21884601 DOI: 10.1186/ar3455] [Cited by in Crossref: 196] [Cited by in F6Publishing: 168] [Article Influence: 19.6] [Reference Citation Analysis]
117 Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70. [PMID: 16308339 DOI: 10.1136/ard.2005.048637] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
118 Mavrogeni SI, Sfikakis PP, Dimitroulas T, Koutsogeorgopoulou L, Katsifis G, Markousis-Mavrogenis G, Kolovou G, Kitas GD. Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. Rheumatol Int 2018;38:949-58. [PMID: 29516170 DOI: 10.1007/s00296-018-4004-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
119 Sparks JA, Barbhaiya M, Karlson EW, Ritter SY, Raychaudhuri S, Corrigan CC, Lu F, Selhub J, Chasman DI, Paynter NP, Ridker PM, Solomon DH. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. Semin Arthritis Rheum 2017;47:133-42. [PMID: 28284844 DOI: 10.1016/j.semarthrit.2017.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
120 Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014;53:2143-54. [PMID: 24907149 DOI: 10.1093/rheumatology/keu224] [Cited by in Crossref: 163] [Cited by in F6Publishing: 123] [Article Influence: 23.3] [Reference Citation Analysis]
121 Dessein PH, Woodiwiss AJ, Joffe BI, Norton GR. Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. BMC Cardiovasc Disord 2007;7:31. [PMID: 17967187 DOI: 10.1186/1471-2261-7-31] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
122 Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry 2010;67:1282-90. [PMID: 21135328 DOI: 10.1001/archgenpsychiatry.2010.160] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 8.1] [Reference Citation Analysis]
123 Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11:229. [PMID: 19519924 DOI: 10.1186/ar2669] [Cited by in Crossref: 491] [Cited by in F6Publishing: 358] [Article Influence: 40.9] [Reference Citation Analysis]
124 Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis Rheumatol 2017;69:1566-75. [PMID: 28425173 DOI: 10.1002/art.40090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
125 Titanji B, Gavegnano C, Hsue P, Schinazi R, Marconi VC. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection. J Am Heart Assoc 2020;9:e014873. [PMID: 31973607 DOI: 10.1161/JAHA.119.014873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
126 Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH, Lindstrom TM, Lee AT, Nishimura T, Zhao L, Morser J, Nesheim M, Goodman SB, Lee DM, Bridges SL Jr, Gregersen PK, Leung LL, Robinson WH; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011;121:3517-27. [PMID: 21804193 DOI: 10.1172/JCI46387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
127 Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol 2013;62:255-62. [PMID: 23792700 DOI: 10.1097/FJC.0b013e31829dd857] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
128 McCoy SS, Crowson CS, Gabriel SE, Matteson EL. Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol 2012;39:954-8. [PMID: 22337246 DOI: 10.3899/jrheum.111076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
129 Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086-1093. [PMID: 19033291 DOI: 10.1136/ard.2008.094474] [Cited by in Crossref: 306] [Cited by in F6Publishing: 208] [Article Influence: 23.5] [Reference Citation Analysis]
130 Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 2015;350:h1269. [PMID: 25770113 DOI: 10.1136/bmj.h1269] [Cited by in Crossref: 67] [Cited by in F6Publishing: 43] [Article Influence: 11.2] [Reference Citation Analysis]
131 Dehpouri T, Rokni GR, Narenjbon NA, Goldust M, Yamauchi PS, Wollina U, Lotti T, Kircik L, Lernia VGD, Sonthalia S, Vojvodic A, Szepietowski J, Bahadoran P, Errichetti E, Cantisani C, Atzori L, Rezaee E, Kutlubay Z, Engin B, Nisticò S, Damiani G, Conic RRZ, Goren A, Čabrijan L, Tchernev G. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Reports 2019;11:7965. [PMID: 31210916 DOI: 10.4081/dr.2019.7965] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
132 Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656-64. [PMID: 18682488 DOI: 10.1093/aje/kwn164] [Cited by in Crossref: 1208] [Cited by in F6Publishing: 987] [Article Influence: 92.9] [Reference Citation Analysis]
133 Hannawi SM, Hannawi H, Al Salmi I. Cardiovascular Risk in Rheumatoid Arthritis: Literature Review. Oman Med J 2021;36:e262. [PMID: 34164156 DOI: 10.5001/omj.2021.25] [Reference Citation Analysis]
134 Branco JC, Barcelos A, de Araújo FP, Sequeira G, Cunha I, Patto JV, Oliveira M, Mateus MP, Couto M, Nero P, Pinto P, Monteiro P, Castelão W, Félix J, Ferreira D, Almeida J, Silva MJ. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study. Adv Ther 2016;33:46-57. [PMID: 26724937 DOI: 10.1007/s12325-015-0276-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
135 Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Helzlsouer KJ. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008;146:802-12.e1. [PMID: 18579112 DOI: 10.1016/j.ajo.2008.04.035] [Cited by in Crossref: 95] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
136 Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, Fearon U, Veale DJ. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther 2021;23:25. [PMID: 33441191 DOI: 10.1186/s13075-020-02380-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
137 Quan LD, Thiele GM, Tian J, Wang D. The Development of Novel Therapies for Rheumatoid Arthritis. Expert Opin Ther Pat. 2008;18:723-738. [PMID: 19578469 DOI: 10.1517/13543776.18.7.723] [Cited by in Crossref: 120] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
138 Mohammad A, Hartery K, Bond U, Phelan M. Increased occurrence of cardiovascular events and comorbidities in a general rheumatology cohort. Ir J Med Sci 2010;179:273-6. [PMID: 20186515 DOI: 10.1007/s11845-010-0475-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
139 Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94. [PMID: 15748099 DOI: 10.2165/00003495-200565050-00006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 4.3] [Reference Citation Analysis]
140 Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther. 2010;12:R197. [PMID: 20964833 DOI: 10.1186/ar3169] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
141 Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, Edwards CJ. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement (N Y) 2017;3:612-21. [PMID: 29201995 DOI: 10.1016/j.trci.2017.10.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
142 Chodara AM, Wattiaux A, Bartels CM. Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches. Curr Rheumatol Rep 2017;19:16. [PMID: 28361332 DOI: 10.1007/s11926-017-0643-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
143 Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004;63:952-5. [PMID: 15051620 DOI: 10.1136/ard.2003.018101] [Cited by in Crossref: 152] [Cited by in F6Publishing: 122] [Article Influence: 8.9] [Reference Citation Analysis]
144 Elliott RA, Putman KD, Franklin M, Annemans L, Verhaeghe N, Eden M, Hayre J, Rodgers S, Sheikh A, Avery AJ. Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER). Pharmacoeconomics 2014;32:573-90. [PMID: 24639038 DOI: 10.1007/s40273-014-0148-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
145 Kelly A, Tymms K, Tunnicliffe DJ, Sumpton D, Perera C, Fallon K, Craig JC, Abhayaratna W, Tong A. Patients' Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis. Arthritis Care Res (Hoboken) 2018;70:525-32. [PMID: 28732151 DOI: 10.1002/acr.23329] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
146 Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs Context 2018;7:212557. [PMID: 30459819 DOI: 10.7573/dic.212557] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
147 Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh DA, Kiely P; ERAS and ERAN. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis 2016;75:2080-6. [PMID: 26979104 DOI: 10.1136/annrheumdis-2015-208669] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 7.2] [Reference Citation Analysis]
148 Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, Oh JK, Matteson EL, Lerman A. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015;12:168-76. [PMID: 25533796 DOI: 10.1038/nrcardio.2014.206] [Cited by in Crossref: 100] [Cited by in F6Publishing: 61] [Article Influence: 14.3] [Reference Citation Analysis]
149 Karaca S, Fidan F, Erkan F, Nural S, Pinarcı T, Gunay E, Unlu M. Might psoriasis be a risk factor for obstructive sleep apnea syndrome? Sleep Breath 2013;17:275-80. [PMID: 22418840 DOI: 10.1007/s11325-012-0686-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
150 Gerhard T, Delaney JA, Cooper-Dehoff RM, Shuster J, Brumback BA, Johnson JA, Pepine CJ, Winterstein AG. Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. BMC Med Res Methodol 2012;12:119. [PMID: 22866767 DOI: 10.1186/1471-2288-12-119] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
151 Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs 2014;74:443-50. [PMID: 24570384 DOI: 10.1007/s40265-014-0190-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
152 Yeoh SA, Fox C, Hull R. Neutropenia in the Elderly: A Rheumatology Perspective. Drugs Aging 2016;33:585-601. [PMID: 27402172 DOI: 10.1007/s40266-016-0383-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Wibetoe G, Sexton J, Ikdahl E, Rollefstad S, Kitas GD, van Riel P, Gabriel S, Kvien TK, Douglas K, Sandoo A, Arts EE, Wållberg-Jonsson S, Dahlqvist SR, Karpouzas G, Dessein PH, Tsang L, El-Gabalawy H, Hitchon CA, Pascual-Ramos V, Contreas-Yañes I, Sfikakis PP, González-Gay MA, Colunga-Pedraz IJ, Galarza-Delgado DA, Azpiri-Lopez JR, Crowson CS, Semb AG. Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. Arthritis Res Ther 2020;22:90. [PMID: 32326974 DOI: 10.1186/s13075-020-02178-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
154 Riegsecker S, Wiczynski D, Kaplan MJ, Ahmed S. Potential benefits of green tea polyphenol EGCG in the prevention and treatment of vascular inflammation in rheumatoid arthritis. Life Sci 2013;93:307-12. [PMID: 23871988 DOI: 10.1016/j.lfs.2013.07.006] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
155 Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002;4:R12. [PMID: 12453315 DOI: 10.1186/ar597] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
156 Klocke R, Cockcroft JR, Taylor GJ, Hall IR, Blake DR. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003;62:414-8. [PMID: 12695151 DOI: 10.1136/ard.62.5.414] [Cited by in Crossref: 114] [Cited by in F6Publishing: 97] [Article Influence: 6.3] [Reference Citation Analysis]
157 van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Twisk JW, van de Stadt RJ, de Koning MH, Habibuw MR, van der Horst-Bruinsma IE, Dijkmans BA. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8. [PMID: 16760255 DOI: 10.1136/ard.2006.051672] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 8.2] [Reference Citation Analysis]
158 Platt RW, Brookhart MA, Cole SR, Westreich D, Schisterman EF. An information criterion for marginal structural models. Stat Med 2013;32:1383-93. [PMID: 22972662 DOI: 10.1002/sim.5599] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
159 Atzeni F, Rodríguez-Carrio J, Popa CD, Nurmohamed MT, Szűcs G, Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol 2021;17:270-90. [PMID: 33833437 DOI: 10.1038/s41584-021-00593-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
160 Kisiel B, Kruszewski R, Juszkiewicz A, Raczkiewicz A, Bachta A, Tłustochowicz M, Staniszewska-Varga J, Kłos K, Duda K, Bogusławska-Walecka R, Płoski R, Tłustochowicz W. Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. J Immunol Res 2015;2015:759610. [PMID: 26090499 DOI: 10.1155/2015/759610] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
161 Cronstein BN. A personal journey from the joint to the heart. Arthritis Res Ther 2010;12:134. [PMID: 20735865 DOI: 10.1186/ar3099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
162 Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev 2013;254:343-54. [PMID: 23772630 DOI: 10.1111/imr.12064] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
163 Bălănescu AR, Bojincă VC, Bojincă M, Donisan T, Bălănescu SM. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med 2019;17:1024-9. [PMID: 30679969 DOI: 10.3892/etm.2018.6992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
164 Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis 2018;275:107-14. [PMID: 29886354 DOI: 10.1016/j.atherosclerosis.2018.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
165 van den Oever IA, van Sijl AM, Nurmohamed MT. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther Adv Musculoskelet Dis 2013;5:166-81. [PMID: 23904862 DOI: 10.1177/1759720X13491025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
166 Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, Tak PP. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1316-21. [PMID: 18723565 DOI: 10.1136/ard.2007.086728] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
167 Lakota K, Hrušovar D, Ogrič M, Mrak-Poljšak K, Čučnik S, Tomšič M, Božič B, Žigon P, Sodin-Semrl S. Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A. Mediators Inflamm 2018;2018:8237209. [PMID: 29670468 DOI: 10.1155/2018/8237209] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
168 Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2010;12:R218. [PMID: 21182767 DOI: 10.1186/ar3203] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
169 Sokka T, Pincus T. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008;47:1543-7. [PMID: 18687711 DOI: 10.1093/rheumatology/ken316] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
170 Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep. 2013;15:295. [PMID: 23225175 DOI: 10.1007/s11883-012-0295-3] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
171 Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2009;11:R51. [PMID: 19344530 DOI: 10.1186/ar2668] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
172 Elsanhoury A, Tschöpe C, Van Linthout S. A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy. J Cardiovasc Transl Res 2021;14:75-87. [PMID: 32440911 DOI: 10.1007/s12265-020-10025-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
173 Pincus T, Sokka T, Chung CP, Cawkwell G. Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials. Ann Rheum Dis 2006;65:878-83. [PMID: 16339290 DOI: 10.1136/ard.2005.044131] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
174 Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010;13:39-75. [PMID: 19888833 DOI: 10.1089/ars.2009.2733] [Cited by in Crossref: 244] [Cited by in F6Publishing: 205] [Article Influence: 24.4] [Reference Citation Analysis]
175 Mankad R, Gabriel SE. Rheumatoid arthritis: treating cardiovascular risk in RA requires multidisciplinary care. Nat Rev Rheumatol 2014;10:202-4. [PMID: 24637364 DOI: 10.1038/nrrheum.2014.37] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
176 Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken) 2010;62:664-75. [PMID: 20461787 DOI: 10.1002/acr.20207] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
177 Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int 2014;2014:367359. [PMID: 25177690 DOI: 10.1155/2014/367359] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
178 Solomon DH, Peters MJ, Nurmohamed MT, Dixon W. Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis. Arthritis Rheum 2013;65:1675-83. [PMID: 23606026 DOI: 10.1002/art.37975] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
179 Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH. Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clin Infect Dis 2019;68:1877-86. [PMID: 30219823 DOI: 10.1093/cid/ciy781] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 23.0] [Reference Citation Analysis]
180 Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. Int J Mol Sci 2019;20:E1599. [PMID: 30935055 DOI: 10.3390/ijms20071599] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 24.5] [Reference Citation Analysis]
181 Kim HJ, Kim MJ, Lee CK, Hong YH. Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis. J Korean Med Sci 2015;30:1589-96. [PMID: 26539002 DOI: 10.3346/jkms.2015.30.11.1589] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
182 Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008;4:605-14. [PMID: 18827910 DOI: 10.2147/vhrm.s2453] [Cited by in Crossref: 72] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
183 Kaplan MJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am. 2010;36:405-426. [PMID: 20510241 DOI: 10.1016/j.rdc.2010.02.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
184 Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 2007;66:341-4. [PMID: 17068067 DOI: 10.1136/ard.2006.057067] [Cited by in Crossref: 64] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
185 Marder W, Khalatbari S, Myles JD, Hench R, Lustig S, Yalavarthi S, Parameswaran A, Brook RD, Kaplan MJ. The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J Am Heart Assoc 2013;2:e000441. [PMID: 24252844 DOI: 10.1161/JAHA.113.000441] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
186 Kiani AN, Vogel-Claussen J, Arbab-Zadeh A, Magder LS, Lima J, Petri M. Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol 2012;39:2286-93. [PMID: 23027889 DOI: 10.3899/jrheum.120197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
187 Scanzello CR, Figgie MP, Nestor BJ, Goodman SM. Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J. 2006;2:141-147. [PMID: 18751827 DOI: 10.1007/s11420-006-9012-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
188 Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep 2008;10:128-33. [PMID: 18417067 DOI: 10.1007/s11883-008-0019-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
189 Uhlig T, Kvien TK. Is rheumatoid arthritis really getting less severe? Nat Rev Rheumatol 2009;5:461-4. [PMID: 19648945 DOI: 10.1038/nrrheum.2009.140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
190 Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009;11:R110. [PMID: 19607680 DOI: 10.1186/ar2765] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
191 Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012;64:1282-91. [PMID: 22504829 DOI: 10.1002/acr.21693] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
192 Incalcaterra E, Accardi G, Balistreri CR, Caimi G, Candore G, Caruso M, Caruso C. Pro-inflammatory genetic markers of atherosclerosis. Curr Atheroscler Rep 2013;15:329. [PMID: 23591672 DOI: 10.1007/s11883-013-0329-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
193 Del Giudice E, Dilillo A, Tromba L, La Torre G, Blasi S, Conti F, Viola F, Cucchiara S, Duse M. Aortic, carotid intima-media thickness and flow- mediated dilation as markers of early atherosclerosis in a cohort of pediatric patients with rheumatic diseases. Clin Rheumatol 2018;37:1675-82. [PMID: 29022136 DOI: 10.1007/s10067-017-3705-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
194 Farragher TM, Lunt M, Bunn DK, Silman AJ, Symmons DP. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007;66:486-92. [PMID: 17090565 DOI: 10.1136/ard.2006.056390] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
195 Zheng Z, Sun Y, Liu Z, Zhang M, Li C, Cai H. The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug Des Devel Ther 2015;9:4931-42. [PMID: 26345159 DOI: 10.2147/DDDT.S90147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
196 Rigby WFC, Lampl K, Low JM, Furst DE. Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. Int J Rheumatol 2017;2017:9614241. [PMID: 29225625 DOI: 10.1155/2017/9614241] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
197 Bergström U, Jovinge S, Persson J, Jacobsson LTH, Turesson C. Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. Curr Ther Res Clin Exp 2018;89:1-6. [PMID: 30128057 DOI: 10.1016/j.curtheres.2018.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
198 Robles-Pérez A, Luburich P, Bolivar S, Dorca J, Nolla JM, Molina-Molina M, Narváez J. A prospective study of lung disease in a cohort of early rheumatoid arthritis patients. Sci Rep 2020;10:15640. [PMID: 32973236 DOI: 10.1038/s41598-020-72768-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
199 Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, Costenbader KH, Karlson EW. Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study. Arthritis Care Res (Hoboken) 2016;68:753-62. [PMID: 26473946 DOI: 10.1002/acr.22752] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 19.3] [Reference Citation Analysis]
200 Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E, Garcia MJ. Anti-inflammatory therapy for cardiovascular disease. Ann Transl Med 2019;7:147. [PMID: 31157268 DOI: 10.21037/atm.2019.02.34] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
201 Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 2010;12:R35. [PMID: 20196859 DOI: 10.1186/ar2944] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
202 Kaplan MJ. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc Health Risk Manag 2008;4:1229-35. [PMID: 19337536 DOI: 10.2147/vhrm.s3461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
203 Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, Mathee S, Dubula V, Ford N, Hernán MA, Boulle A. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One 2013;8:e56088. [PMID: 23418518 DOI: 10.1371/journal.pone.0056088] [Cited by in Crossref: 136] [Cited by in F6Publishing: 133] [Article Influence: 17.0] [Reference Citation Analysis]
204 Jämsen E, Virta LJ, Hakala M, Kauppi MJ, Malmivaara A, Lehto MU. The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. Acta Orthop 2013;84:331-7. [PMID: 23992137 DOI: 10.3109/17453674.2013.810519] [Cited by in Crossref: 62] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
205 Zhang R, Chen S, Zhang H, Liu Q, Xing J, Zhao Q, Wang Y, Yu B, Hou J. Effects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study. Sci Rep 2016;6:33657. [PMID: 27644847 DOI: 10.1038/srep33657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
206 Paskins Z, Whittle R, Sultan AA, Muller S, Blagojevic-Bucknall M, Helliwell T, Hider S, Roddy E, Mallen C. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med 2018;16:4. [PMID: 29316928 DOI: 10.1186/s12916-017-0987-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
207 Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 2008;67:358-63. [PMID: 17666451 DOI: 10.1136/ard.2007.071662] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
208 Solow EB, Yu F, Thiele GM, Sokolove J, Robinson WH, Pruhs ZM, Michaud KD, Erickson AR, Sayles H, Kerr GS, Gaffo AL, Caplan L, Davis LA, Cannon GW, Reimold AM, Baker J, Schwab P, Anderson DR, Mikuls TR. Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. Rheumatology (Oxford) 2015;54:1587-95. [PMID: 25854268 DOI: 10.1093/rheumatology/kev027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
209 Rho YH, Oeser A, Chung CP, Milne GL, Stein CM. Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf 2009;2:34-40. [PMID: 19684849 DOI: 10.1111/j.1753-5174.2009.00019.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
210 Rho YH, Oeser A, Chung CP, Morrow JD, Stein CM. Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf 2008;1:23-8. [PMID: 20157365 DOI: 10.1111/j.1753-5174.2007.00004.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
211 Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33. [PMID: 15140767 DOI: 10.1136/ard.2003.011395] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
212 Ramiro S, Machado P, Singh JA, Landewé RB, da Silva JA. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Res Ther 2010;12:220. [PMID: 21067530 DOI: 10.1186/ar3149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
213 Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010;12:R71. [PMID: 20423475 DOI: 10.1186/ar2989] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
214 Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, Drosos AA. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther 2006;8:R82. [PMID: 16646989 DOI: 10.1186/ar1952] [Cited by in Crossref: 135] [Cited by in F6Publishing: 116] [Article Influence: 9.0] [Reference Citation Analysis]
215 Hsue PY, Scherzer R, Grunfeld C, Imboden J, Wu Y, Del Puerto G, Nitta E, Shigenaga J, Schnell Heringer A, Ganz P. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc. 2014;3:e001267. [PMID: 25336464 DOI: 10.1161/jaha.114.001267] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
216 Chester Wasko M, Dasgupta A, Ilse Sears G, Fries JF, Ward MM. Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken) 2016;68:706-10. [PMID: 26415107 DOI: 10.1002/acr.22722] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
217 Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2009;11:217. [PMID: 19435478 DOI: 10.1186/ar2631] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
218 Patel MJ, Blazing MA. Inflammation and atherosclerosis: disease modulating therapies. Curr Treat Options Cardiovasc Med 2013;15:681-95. [PMID: 23979859 DOI: 10.1007/s11936-013-0268-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
219 Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 2015;7:187-95. [PMID: 26425147 DOI: 10.1177/1759720X15591801] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
220 Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509. [PMID: 24161836 DOI: 10.1136/annrheumdis-2013-204573] [Cited by in Crossref: 1333] [Cited by in F6Publishing: 1057] [Article Influence: 166.6] [Reference Citation Analysis]
221 Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009;68:930-7. [PMID: 18829616 DOI: 10.1136/ard.2008.092734] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
222 Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, Jiang Z, Wang Y, Yu C, Wang Q, Tian X, Zhao Y, Zeng X; CREDIT Co-authors. Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther 2017;19:251. [PMID: 29141688 DOI: 10.1186/s13075-017-1457-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
223 Hudson M, Steele R, Baron M; Canadian Scleroderma Research Group. Immunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research. J Cell Commun Signal 2012;6:187-90. [PMID: 22865262 DOI: 10.1007/s12079-012-0172-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
224 Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11. [PMID: 15208176 DOI: 10.1136/ard.2004.023408] [Cited by in Crossref: 93] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
225 Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008;121:S3-8. [PMID: 18926167 DOI: 10.1016/j.amjmed.2008.06.010] [Cited by in Crossref: 154] [Cited by in F6Publishing: 122] [Article Influence: 11.8] [Reference Citation Analysis]
226 Owczarczyk-Saczonek A, Czerwiñska J, Orylska M, Placek W. Effect of methotrexate treatment on the expression of epidermal-fatty acid-binding protein (E-FABP) and apolipoproteins in patients with psoriasis. Postepy Dermatol Alergol 2020;37:401-6. [PMID: 32792883 DOI: 10.5114/ada.2020.96109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int. 2011;31:153-164. [PMID: 20390282 DOI: 10.2174/138161211795049804] [Cited by in Crossref: 622] [Cited by in F6Publishing: 455] [Article Influence: 62.2] [Reference Citation Analysis]
228 Shapiro M, Levy Y. The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. Oncotarget 2018;9:6615-22. [PMID: 29464097 DOI: 10.18632/oncotarget.23570] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
229 Wright K, Crowson CS, Gabriel SE. Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure. Heart Fail Clin 2014;10:339-52. [PMID: 24656110 DOI: 10.1016/j.hfc.2013.10.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
230 Boyer JF, Balard P, Authier H, Faucon B, Bernad J, Mazières B, Davignon JL, Cantagrel A, Pipy B, Constantin A. Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther 2007;9:R22. [PMID: 17335569 DOI: 10.1186/ar2133] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
231 van Steenbergen HW, Rodríguez-Rodríguez L, Berglin E, Zhernakova A, Knevel R, Ivorra-Cortés J, Huizinga TW, Fernández-Gutiérrez B, Gregersen PK, Rantapää-Dahlqvist S, van der Helm-van Mil AH. A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Res Ther 2015;17:1. [PMID: 25566937 DOI: 10.1186/s13075-014-0514-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
232 Seto Y, Tanaka E, Inoue E, Nakajima A, Taniguchi A, Momohara S, Yamanaka H. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol 2011;21:579-93. [PMID: 21424533 DOI: 10.1007/s10165-011-0445-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
233 Power MC, Tchetgen EJ, Sparrow D, Schwartz J, Weisskopf MG. Blood pressure and cognition: factors that may account for their inconsistent association. Epidemiology 2013;24:886-93. [PMID: 24030502 DOI: 10.1097/EDE.0b013e3182a7121c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
234 Teague H, Mehta NN. The Link Between Inflammatory Disorders and Coronary Heart Disease: a Look at Recent Studies and Novel Drugs in Development. Curr Atheroscler Rep 2016;18:3. [PMID: 26739273 DOI: 10.1007/s11883-015-0557-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
235 Peters MJ, Vis M, van Halm VP, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BA, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958-61. [PMID: 17314120 DOI: 10.1136/ard.2006.059691] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
236 Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. [PMID: 25561362 DOI: 10.1136/annrheumdis-2014-206624] [Cited by in Crossref: 428] [Cited by in F6Publishing: 320] [Article Influence: 71.3] [Reference Citation Analysis]
237 Chen J, Norling LV, Cooper D. Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells 2021;10:881. [PMID: 33924323 DOI: 10.3390/cells10040881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]